Najera; Isabel

Patent Applications and Registrations

Patent applications and USPTO patent grants for Najera; Isabel.The latest application filed is for "combination therapy of an hbv capsid assembly inhibitor and an interferon".

Company Profile

5.8.18

Najera; Isabel - Basel CH
Najera; Isabel - Madrid ES
Najera; Isabel - Menlo Park CA
NAJERA; ISABEL - PORTOLA VALLEY CA
Najera, Isabel - St. Albans GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination Therapy Of An Hbv Capsid Assembly Inhibitor And An Interferon App 20200276198 - Gao; Lu ; et al.	2020-09-03
Combination therapy of an HBV capsid assembly inhibitor and an interferon Grant 10,596,173 - Gao , et al.	2020-03-24
Pyridazinone-based broad spectrum anti-influenza inhibitors Grant 10,597,380 - Cumming , et al.	2020-03-24
Combination Therapy Of An Hbv Capsid Assembly Inhibitor And A Nucleos(t)ide Analogue App 20190275052 - Najera; Isabel ; et al.	2019-09-12
Pyridazinone-based Broad Spectrum Anti-influenza Inhibitors App 20190127349 - CUMMING; John G. ; et al.	2019-05-02
Combination Therapy Of An Hbv Capsid Assembly Inhibitor And An Interferon App 20180250301 - Gao; Lu ; et al.	2018-09-06
4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication Grant 8,648,054 - Devos , et al. February 11, 2	2014-02-11
4'-substituted Nucleoside Derivatives As Inhibitors Of Hcv Rna Replication App 20130237491 - Devos; Rene Robert ; et al.	2013-09-12
4'-substituted Nucleoside Derivatives As Inhibitors Of Hcv Rna Replication App 20120034184 - Devos; Rene Robert ; et al.	2012-02-09
4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication Grant 8,071,567 - Devos , et al. December 6, 2	2011-12-06
HCV NS5A Replicon Shuttle Vectors App 20110245328 - Kang; Hyunsoon ; et al.	2011-10-06
4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication Grant 7,915,232 - Martin , et al. March 29, 2	2011-03-29
Hcv Ns3/4a Replicon Shuttle Vectors App 20110053160 - ALI; SAMIR ; et al.	2011-03-03
Production Of Infectious Hepatitis C Virus Particles In Cell Culture App 20100068698 - McCown; Matthew F. ; et al.	2010-03-18
4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication App 20100004192 - Martin; Joseph Armstrong ; et al.	2010-01-07
4'-substituted Nucleoside Derivatives As Inhibitors Of Hcv Rna Replication App 20100003213 - Devos; Rene Robert ; et al.	2010-01-07
4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication Grant 7,608,601 - Devos , et al. October 27, 2	2009-10-27
HCV NS3 replicon shuttle vectors App 20090004664 - Chua; Pong Kian ; et al.	2009-01-01
HCV replicon shuttle vectors App 20080026952 - Dietrich; Paul Shartzer ; et al.	2008-01-31
4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication App 20040266722 - Devos, Rene Robert ; et al.	2004-12-30
4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Grant 6,784,166 - Devos , et al. August 31, 2	2004-08-31
Anti-HCV nucleoside derivatives App 20040110718 - Devos, Rene ; et al.	2004-06-10
4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication App 20030236216 - Devos, Rene Robert ; et al.	2003-12-25
Anti-HCV nucleoside derivatives Grant 6,660,721 - Devos , et al. December 9, 2	2003-12-09
Anti-HCV nucleoside derivatives App 20030083307 - Devos, Rene Robert ; et al.	2003-05-01
Anti-HCV nucleoside derivatives App 20030008841 - Devos, Rene ; et al.	2003-01-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.